@paulg: It was the best of times, it was the worst of times.

X AI KOLs Following News
medicine glp-1 cancer-drug retatrutide pancreatic-cancer pharma

Summary

Derek Thompson highlights recent medical breakthroughs including an effective GLP-1 drug from Eli Lilly and a promising new pancreatic cancer drug from Revolution Medicines.

It was the best of times, it was the worst of times.
Original Article
View Cached Full Text

Cached at: 06/01/26, 01:03 AM

It was the best of times, it was the worst of times.

Derek Thompson (@DKThomp): This has quietly been a miracle month in medicine.

In the last 5 weeks we’ve got news on:

  • retatrutide, the triple agonist GLP-1 from Lilly, basically melting fat and body-wide inflammation at record levels
  • RevMed’s new pancreatic cancer drug showing unprecedented

Similar Articles

@FinanceYF5: 3/7 From the very beginning, Mithril was a virtual, decentralized, extremely lean company. This kind of model is usually difficult to sustain for long, but as AI tools rapidly matured, the company operated for quite some time with “one operator + lots of Claude + part-time advisors.” Later, it gradually became an experiment: one person…

X AI KOLs Following

The tweet describes Mithril, an extremely lean, virtually operated drug R&D company that has sustained its operations through a model of “one operator + extensive use of Claude AI + part-time consultants,” evolving into an experiment in how far an individual can advance a drug R&D company with the help of AI.